LGL Partners’s AbbVie ABBV Stock Holding History

LGL Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,080	Closed	-$413K	–	94
2022 Q3	$413K	Buy	+3,080	New	+$442K	0.09%	74

Other funds holding ABBV

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LGL Partners's ABBV Position: Q4 2022 in Review

LGL Partners sold out of AbbVie (ABBV) in Q4 2022, closing a stake of 3,080 shares — an estimated $413K sold.

LGL Partners first reported a position in ABBV in Q3 2022 and held it in 1 quarter. The position peaked at $413K in Q3 2022. 3,168 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

LGL Partners reported no remaining AbbVie position as of Q4 2022 after selling out during the quarter.
LGL Partners sold 3,080 AbbVie shares in Q4 2022, an estimated $413K.
LGL Partners first reported a position in AbbVie in Q3 2022 and held it in 1 quarter.
LGL Partners's AbbVie position peaked at $413K in Q3 2022.
3,168 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on LGL Partners's 13F filing for Q4 2022, filed 14 Feb 2023.